Save the date: Uncover best practices and new insights in chemical safety decision-making with Lhasa
Coming to Colombia on 10 March 2026!
Lhasa Limited is pleased to announce that we will host a symposium in Bogotá, Colombia in March 2026.
For our trip to South America to co-host an event with our subsidiary, Consult Lhasa, we have tailored the agenda to address regional regulatory expectations while aligning with international best practices for chemical safety assessments.
We’ll equip attendees with the latest knowledge and developments in pharmaceutical science, in silico methodologies, and regulatory compliance.
The symposium offers the opportunity to collaborate, discuss, and explore key topics in in silico and pharmaceutical science. Key topics include impurity degradation, managing nitrosamine and genotoxicity impurities, mutagenic risk assessment fundamentals, and confident regulatory-aligned control.
Lhasa will engage industry experts and researchers from across the predictive science and regulatory landscape to explore topics that advance confident and expert-led chemical safety decision making.
Event Details
Date: Friday 10th March 2026
Location: Hotel Capital GHL, Fontibón, Bogotá, Cundinamarca, Colombia
Meeting Agenda:
-
Session 1 – Understanding, predicting, and managing degradation-related risks
Diego Zulkiewicz Gomes, Global Alliances Manager at Lhasa Limited, will explore drug-excipient compatibility in stability, specifically degradation products.
Expert Fernando Castro, Universidad del Atlantico, will showcase in silico tools for drug development before we delve into a case study from Jhojanis Rodriguez, Procaps.
-
Session 2 – Applying ICH M7 in a practical and defensible way
Lucia Toscano, Application Scientist at Lhasa Limited, will discuss the complete theoretical workflow of mutagenicity risk assessments in line with ICH M7 guidelines, from identification onwards.
Delving into specific in silico tools, we’ll showcase implementation for risk assessments according to ICH M7. Maria Celeste Del Fueyo will also highlight the integration of ICH Q3D and rias based approached for elemental impurities in the context of overall risk assessment.
-
Session 3 – Nitrosamines: from risk identification to regulatory justification
Gabriela Silveira, Lead Scientific Consultant at Consult Lhasa provides insight into the current regulatory landscape and global expectations for nitrosamines in pharmaceutical products, exploring acceptable intakes and surrogate selection for nitrosamines.
Experts on nitrosamine risk assessments in practice, Spektra Consultoria (a Consult Lhasa subsidiary), will also explore conservative risk calculations in assessment practice.
-
Session 4 – Future regulatory challenges we can prepare for today
Key regulatory authorities and industry experts will delve into emerging topics in pharmaceutical regulations. We’ll touch on current expectations in Colombia, perspectives on impurities and nitrosamines, regulatory harmonisation in LATAM, extractables and leachables, and more. Further details to come!
If this date or location isn’t a fit, we will continue conversations at our Argentina symposium, taking place only a few days later! The event features its own program and regional perspectives, but explores complementary themes.